Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

asciminib

Novartis building

Novartis to deliver three million malaria treatments in Zambia

Part of Malaria No More’s Power of One campaign

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

- PMLiVE

Pfizer gets FDA nod for meningitis vaccine Trumenba

Ahead of Novartis’ rival drug Bexsero

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

Novartis building

Novartis sells flu vaccines business to CSL for $275m

Follows the Swiss pharma company's asset swap deals with GSK

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

Novartis building

FDA panel backs Novartis’ secukinumab for psoriasis

Drug has outperformed Amgen’s Enbrel in clinical trials

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

Novartis building

Novartis’ secukinumab has ‘consistent’ activity in psoriasis

Reinforces data that suggests drug is more effective than Amgen’s Enbrel

- PMLiVE

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

- PMLiVE

Novartis’ Bexsero triumphs at UK Prix Galien

The Awards also saw Janssen's Sirturo pick up the Orphan Drug prize

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links